智通财经网·2025-12-02 13:09Core Viewpoint - Fosun Pharma's subsidiary, Suzhou Er Ye Pharmaceutical, has received acceptance for the drug registration application of sodium heparin injection from the National Medical Products Administration of China, indicating progress in the commercialization of this self-developed chemical drug [1] Company Summary - The sodium heparin injection is intended for multiple medical uses, including the prevention and treatment of venous thrombosis and pulmonary embolism, as well as anticoagulation during surgeries and dialysis [1] - As of October 2025, the cumulative R&D investment for this drug by Suzhou Er Ye is approximately RMB 8.61 million (unaudited) [1] Market Summary - According to the latest IQVIA CHPA data, the sales revenue of sodium heparin injection in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be approximately RMB 1.386 billion in 2024 [1] - The drug must obtain regulatory approval before commercial production can commence, but the acceptance of the application will not have a significant impact on the current performance of the group [1]